Delayed thrombocytopenia following administration of abciximab: Pharmacovigilance survey and literature review

Vincent, Louis; Bourneau‐Martin, Delphine; Maurier, Anaïs; Babin, Marina; Delépine, Stéphane; Helley, Dominique; Grandvuillemin, Aurélie; Lagarce, Laurence; Louët, Agnés Lillo‐Le; Briet, Marie

doi:10.1016/j.therap.2021.02.006

Cited by 3 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abciximab is a chimeric human/mouse antibody directed against the integrin aIIbb3 receptor that binds to integrin avb3 on the tumor and endothelial cells leading to integrin aMb2 expression on leukocytes. This cross-reactivity on both platelets and endothelial cells may contribute to the inhibition of tumor angiogenesis (140).…”

Section: Platelet Integrinsmentioning

confidence: 99%

Emerging roles of platelets in cancer biology and their potential as therapeutic targets

et al. 2022

View full text Add to dashboard Cite

The main role of platelets is to control bleeding and repair vascular damage via thrombosis. They have also been implicated to promote tumor metastasis through platelet-tumor cell interactions. Platelet-tumor cell interactions promote tumor cell survival and dissemination in blood circulation. Tumor cells are known to induce platelet activation and alter platelet RNA profiles. Liquid biopsies based on tumor-educated platelet biomarkers can detect tumors and correlate with prognosis, personalized therapy, treatment monitoring, and recurrence prediction. Platelet-based strategies for cancer prevention and tumor-targeted therapy include developing drugs that target platelet receptors, interfere with the release of platelet particles, inhibit platelet-specific enzymes, and utilize platelet-derived “nano-platelets” as a targeted drug delivery platform for tumor therapy. This review elaborates on platelet-tumor cell interactions and the molecular mechanisms and discusses future research directions for platelet-based liquid biopsy techniques and platelet-targeted anti-tumor strategies.

show abstract

Section: Platelet Integrinsmentioning

confidence: 99%

Emerging roles of platelets in cancer biology and their potential as therapeutic targets

et al. 2022

View full text Add to dashboard Cite

show abstract

“…9 Literature review done in 2021, showed that thrombocytopenia is seen in patients within 24 hours of treatment with abciximab. 10 Many cases of thrombocytopenia has been reported with abciximab but the incidence of severe thrombocytopenia is low and only a few have been reported from India.…”

Section: Discussionmentioning

confidence: 99%

Abciximab induced severe thrombocytopenia in an elderly patient

Sen

Bhatti

Joseph

et al. 2022

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Abciximab is a humanized monoclonal antibody which acts against αIIbβ3 receptor. The use of abciximab with percutaneous coronary interventions (PCI) has proven good results in patients. The drug has been notorious to cause bleeding and also decrease in the number of platelets. In this case the patient had normal platelet count but the count decreased significantly after abciximab was given. A number of cases have been reported but very few have been reported from India. Hence, we found it important to report and it is a valuable asset for scientific research.

show abstract

“…Abciximab (ABX) is a fragment of the monoclonal antibody 7E3 that binds the platelet receptor glycoprotein (GPIIb/IIIa) [ 44 ]. (ABX) has the strongest antiaggregant with a particular characteristic that predisposes patients to a higher incidence of both mild <100.000 cell/μL and severe < 50.000 cells/μL thrombocytopenia [ 39 , 45 ] by preventing the binding of fibrinogen and Von Willebrand Factor to GPIIb/IIIa receptor on activated platelets, showing a quick action, peak plasma concentration, and platelet inhibition achieved 10 minutes after IV injection [ 46 ].…”

Section: Reviewmentioning

confidence: 99%

Adverse Drug Effect Profiles of Gp2b/3a Inhibitors: A Comparative Review of the Last Two Decades

Hasan,

Jauregui,

Zubair

et al. 2023

Cureus

View full text Add to dashboard Cite

ST-Elevation Myocardial Infarction and non-ST Elevation Myocardial Infarction belong to the acute coronary syndrome group of diseases. These conditions are characterized by the complete or partial blockage of one or several coronary arteries, resulting in myocardial injury or necrosis. Various medications are used in their treatment, with the most recent addition being Glycoprotein IIb/IIIa inhibitors. They work by hindering the activity of glycoprotein IIb/IIIa receptors, which, in turn, prevents the clumping of platelets. Some of the GpIIb/IIIa inhibitors available in this category include abciximab, tirofiban, eptifibatide, roxifiban, and orbofiban. With this comprehensive literature review, we aimed to explore the potential adverse effects of these medications and compare the three in terms of their side effects profile. We searched through PubMed and Google Scholar and pinpointed 13 articles aligned with our inclusion criteria: six articles utilized eptifibatide, four were related to abciximab, and three used tirofiban. In 85% of the cases, a severe drop in platelet count, reaching as low as 1000/μL, was reported. Additionally, several other side effects were noted: one case documented multiple bruising spots appearing around the patient's body, two cases reported diffuse alveolar hemorrhage, and one case described a cardiac tamponade resulting from hemorrhagic pericarditis. Our study highlights the crucial significance of keeping a watchful eye on and comprehending the potential drawbacks linked to these medications in cardiovascular treatment. The necessity of researching these medications and their side effects is also evident, as this will significantly enhance the quality of treatment provided.

show abstract

Delayed thrombocytopenia following administration of abciximab: Pharmacovigilance survey and literature review

Cited by 3 publications

References 22 publications

Emerging roles of platelets in cancer biology and their potential as therapeutic targets

Emerging roles of platelets in cancer biology and their potential as therapeutic targets

Abciximab induced severe thrombocytopenia in an elderly patient

Adverse Drug Effect Profiles of Gp2b/3a Inhibitors: A Comparative Review of the Last Two Decades

Contact Info

Product

Resources

About